Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898662 | 0.89 | NOTUM (0.33) | NOTUMMEN1KMT2APOLBMAPK8 | |
| SCHEMBL4903207 | 0.86 | NOTUM (0.37) | NOTUMMEN1KMT2APOLBMAPK8 | |
| SCHEMBL4893908 | 0.85 | PTPN2 (0.39) | NOTUMMEN1KMT2AMAPK8MAPT | |
| SCHEMBL4894893 | 0.78 | PTPN1 (0.33) | — | |
| SCHEMBL4897222 | 0.77 | NOTUM (0.38) | NOTUMMEN1KMT2APOLBMAPK8 | |
| SCHEMBL5817911 | 0.76 | PTPN1 (0.42) | NOTUMMAPK8MAPTSMN1; SMN2 | |
| SCHEMBL4901446 | 0.76 | — | — | |
| SCHEMBL4903728 | 0.75 | MAPK10 (0.40) | NOTUMMEN1KMT2AMAPK8SMN1; SMN2 | |
| SCHEMBL4903121 | 0.75 | MAPK10 (0.40) | NOTUMMEN1KMT2AMAPK8SMN1; SMN2 | |
| SCHEMBL4890553 | 0.75 | PTPN1 (0.40) | NOTUMMAPK8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | PPM1B, PPM1D, PTPRS | NOTUM 4398/4885MEN1 3587/4885KMT2A 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.